Cargando…

A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report

Neuroendocrine tumors (NET) are rare and demonstrate variable clinical behavior depending on the degree of tumor differentiation. Patients with poorly differentiated tumors (NET G3) have a poor prognosis. Systemic treatment with cytotoxic chemotherapy is considered to be the treatment of choice. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Özdirik, Burcin, Amthauer, Holger, Schatka, Imke, Goretzki, Peter E., Mogl, Martina T., Fehrenbach, Uli, Tacke, Frank, Jann, Henning, Roderburg, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725216/ https://www.ncbi.nlm.nih.gov/pubmed/33363730 http://dx.doi.org/10.3892/mco.2020.2182

Ejemplares similares

A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments
por: Özdirik, Burcin, et al.
Publicado: (2020)

PD-L1 – inhibitors in neuroendocrine neoplasia: Results from a real-life study
por: Özdirik, Burcin, et al.
Publicado: (2021)

The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
por: Ruhwedel, Tristan, et al.
Publicado: (2021)

Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review
por: Özdirik, Burcin, et al.
Publicado: (2020)

Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
por: Roderburg, Christoph, et al.
Publicado: (2020)

The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
por: Wetz, Christoph, et al.
Publicado: (2019)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors
por: Geisler, Lukas, et al.
Publicado: (2021)

Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI—A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making
por: Fehrenbach, Uli, et al.
Publicado: (2021)

Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
por: Wetz, Christoph, et al.
Publicado: (2020)

Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors
por: Hellberg, Teresa, et al.
Publicado: (2020)

Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors
por: Reinhard, Lisa, et al.
Publicado: (2023)

Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021)

In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?
por: Mohr, Raphael, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score
por: Schatka, Imke, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
por: Noorali, Sima, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors
por: Al-Toubah, Taymeyah, et al.
Publicado: (2022)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
por: Kotteas, Elias A, et al.
Publicado: (2016)

Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
por: Özdirik, Burcin, et al.
Publicado: (2020)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC
por: Galler, Markus, et al.
Publicado: (2022)

Insulinoma in pregnancy (a case presentation and systematic review of the literature)
por: Dobrindt, Eva M, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
por: Ünal, Çağlar, et al.
Publicado: (2023)

Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review
por: Ishida, Atsushi, et al.
Publicado: (2022)

Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis
por: Lu, Yaoheng, et al.
Publicado: (2018)

Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience
por: Douangprachanh, Sathathone, et al.
Publicado: (2022)

MON-406 Two Cases of Aggressive Corticotroph Pituitary Tumors Treated with Capecitabine and Temozolomide
por: Tateno, Tae, et al.
Publicado: (2019)

The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2021)

Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review
por: Zhang, Bin, et al.
Publicado: (2019)

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
por: Mohr, Raphael, et al.
Publicado: (2021)

Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023)

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2021)

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies
por: Bison, Sander M., et al.
Publicado: (2015)

From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis
por: Mohr, Raphael, et al.
Publicado: (2021)

Combination Therapies with PRRT
por: Yordanova, Anna, et al.
Publicado: (2021)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kqvtp9g955joi1dt1gmucnnn2d